Matthew S. Sutton

Matthew S. Sutton

Auto-generated profile, based on publicly available information

Matthew S. Sutton

Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda Maryland USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2025 in Journal of Experimental Medicine
Verified
Journal Article
Open access
ASAndrew W. Simonson
Andrew W. Simonson
JZJoseph J. Zeppa
Joseph J. Zeppa
ABAllison N. Bucsan
Allison N. Bucsan
SPSupriya Pokkali
Supriya Pokkali
FHForrest Hopkins
Forrest Hopkins
JFJoAnne L. Flynn
JoAnne L. Flynn
Tuberculosis (TB) is a major health burden worldwide despite widespread intradermal (ID) BCG vaccination in newborns. We previously demonstrated that changing the BCG route and dose from 5 × 105 CFUs ID to 5 × 107 CFUs i.v. resulted in prevention of Mycobacterium tuberculosis (Mtb) infection and TB disease in highly susceptible nonhuman primates. Identifying immune mechanisms protection following i.v. BCG will facilitate development of more effective vaccines against TB. Here, we depleted lymphocyte subsets prior to and during Mtb challenge in i.v. BCG–vaccinated macaques to identify those necessary for protection. Depletion of adaptive CD4 T cells, but not adaptive CD8αβ T cells, resulted in loss of protection with increased Mtb burdens and dissemination, indicating that CD4 T cells are critical to i.v. BCG–mediated protection. Depletion of unconventional CD8α-expressing lymphocytes (NK cells, innate T cells, and CD4+CD8α+ double-positive T cells) abrogated protection in most i.v. BCG–immunized macaques, supporting further investigation into which of these cell subsets contribute to protection after vaccination.

3 January 2025 in Science Advances
Verified
Journal Article
Open access
JPJoshua M. Peters
Joshua M. Peters
EIEdward B. Irvine
Edward B. Irvine
MMMohau S. Makatsa
Mohau S. Makatsa
JRJacob M. Rosenberg
Jacob M. Rosenberg
MWMarc H. Wadsworth
Marc H. Wadsworth
BBBryan D. Bryson
Bryan D. Bryson
Intradermal Bacillus Calmette-Guérin (BCG) is the most widely administered vaccine, but it does not sufficiently protect adults against pulmonary tuberculosis. Recent studies in nonhuman primates show that intravenous BCG administration offers superior protection against Mycobacterium tuberculosis ( Mtb ). We used single-cell analysis of bronchoalveolar lavage cells from rhesus macaques vaccinated via different routes and doses of BCG to identify alterations in the immune ecosystem in the airway following vaccination. Our findings reveal that high-dose intravenous BCG induces an influx of polyfunctional T cells and macrophages in the airways, with alveolar macrophages from high-dose intravenous BCG displaying a basal activation state in the absence of purified protein derivative stimulation, defined in part by interferon signaling. Enhanced intercellular immune signaling and stronger T helper 1–T helper 17 transcriptional responses were observed following purified protein derivative stimulation. These results suggest that high-dose intravenous BCG vaccination creates a specialized immune environment that primes airway cells for effective Mtb clearance.

20 August 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
VCVictoria Callahan
Victoria Callahan
MSMatthew S. Sutton
Matthew S. Sutton
CGChristina L. Gardner
Christina L. Gardner
JPJessica Prado-Smith
Jessica Prado-Smith
DKDoreswamy Kenchegowda
Doreswamy Kenchegowda
JFJulie Fox
Julie Fox
Alphaviruses are emerging public health threats. Broadly reactive anti-alphavirus monoclonal antibodies (mAbs) have been shown to be protective in mouse models of infection. However, the antibody characteristics that promote in vivo efficacy and dependency on Fc effector functions remain ill defined. Here, we used two vaccine-elicited, broadly reactive, anti-alphavirus mAbs, SKT05 and SKT20, to establish correlates of mAb-mediated protection during Venezuelan equine encephalitis virus (VEEV) challenge. SKT20 required Fc effector functions to prevent lethality. The necessity of Fc effector functions for SKT20 was dose dependent and related to mAb binding potency and pseudovirus neutralization rather than epitope specificity. In contrast, survival mediated by SKT05 when given prophylactically was independent of Fc effector functions and rather was linked to early viral control through egress inhibition. However, control of virus replication and spread with SKT05 at later time points was Fc dependent. Therapeutic administration of SKT05 required Fc effector functions only at 3 days after infection. These findings extended to additional in vivo infection models with alternative VEEV subtypes and with chikungunya virus. Collectively, this study identified binding potency and pseudoviral neutralization as correlates for in vivo efficacy of mAbs and demonstrated that Fc-dependent mechanisms can be leveraged for development of therapeutic mAbs against emerging alphaviruses.

14 August 2026 in Advanced Science
Verified
Journal Article
Open access
JCJiaxuan Cheng
Jiaxuan Cheng
ECEvan M. Cale
Evan M. Cale
AMAmirabbas Maghsoudi
Amirabbas Maghsoudi
MSMatthew S. Sutton
Matthew S. Sutton
NLNancy S. Longo
Nancy S. Longo
TZTongqing Zhou
Tongqing Zhou
Viral entry glycoproteins are often shielded from immune recognition by dense N ‐linked glycans that limit antibody access to protein epitopes. While glycan‐reactive antibodies with unusual architectures have been described, how canonical Y‐shaped antibodies engage these glycan‐rich surfaces remains poorly defined. Here, we characterize two human antibodies, VRC35 and VRC36, isolated from an HIV‐1‐infected donor, that recognize diverse glycosylated viral glycoproteins. Cryo‐electron microscopy structural analyses of these antibodies in complex with viral entry glycoproteins, including HIV‐1 envelope, influenza hemagglutinin, SARS‐CoV‐2 spike, and the Lassa virus glycoprotein complex, reveal adaptive Fab stoichiometries ranging from single‐Fab binding to dimeric and higher‐order assemblies are mediated by intra‐ and inter‐IgG interactions that depend on local glycan organization. Dense glycan clustering on HIV‐1 and influenza glycoproteins supports multivalent Fab assemblies and correlates with neutralization activity, whereas sparse glycan environments on SARS‐CoV‐2 and Lassa virus favor weak or heterogeneous engagement without neutralization. Structural and mutational analyses further demonstrate that homotypic Fab–Fab interactions stabilize multivalent engagement and contribute to neutralizing activity. Together, these findings define a structural framework in which viral glycan organization constrains antibody valency and engagement, while somatic hypermutation contributes to the acquisition of homotypic Fab‐Fab interactions that facilitate multivalent recognition of viral glycan shields.